NextCell Pharma
1.31 SEK
0.00 %
Less than 1K followers
NXTCL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for NextCell Pharma
EV/S
Median 2019-2021
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 3.67 | 7.47 | 11.45 | 5.02 | 2.84 | 1.27 | 1.17 |
| Shares | 23.6 | 27.0 | 29.6 | 20.0 | 20.0 | 60.0 | 111.4 |
| Market cap | 86.4 | 202.0 | 339.3 | 100.5 | 57.0 | 76.2 | 130.3 |
| Enterprise value | 66.3 | 180.0 | 200.1 | - | - | - | - |
| EV/S | 36.6 | 50.5 | 51.2 | - | - | - | - |
| EV/EBITDA | neg. | neg. | neg. | - | - | - | - |
| EV/EBIT | neg. | neg. | neg. | - | - | - | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 3.77 | 7.70 | 2.26 | 0.87 | 0.75 | 1.13 | 1.96 |
| P/S | 47.7 | 56.7 | 86.7 | 18.0 | 5.6 | 7.1 | 11.9 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 85.9 % | 88.1 % | 96.4 % | 92.7 % | 85.3 % | 83.2 % | 86.5 % |
| Gearing ratio | - | - | - | - | - | - | - |